Trials / Terminated
TerminatedNCT00277316
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Symphony Evolution, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL999 | Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion. |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2007-02-01
- Completion
- 2007-06-01
- First posted
- 2006-01-16
- Last updated
- 2010-02-19
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00277316. Inclusion in this directory is not an endorsement.